Document is current
Any future updates will be listed below
-
Authors
Sindrewicz-Goral, Paulina
Li, Xiaoxin
Wang, Weikun
Adegbite, Oluwatobi
Pang, Yaoyu
Gledhill, Thomas
Sreenivas, Sandra
Lian, Lu-Yun
Yu, Lu-Gang
-
Funding
Funding for this research was provided by:
Medical Research Council,United Kingdom (MR/L014327/1)
- License Information
-
More Information
Article History
Received: 11 June 2025
Accepted: 21 August 2025
First Online: 29 September 2025
Declarations
:
: Not applicable.
: Not applicable.
: LGY holds shares in Galytx Ltd which develops galectin-3-targeted therapeutic drugs. The others declare no conflict of interest.
